Home » Stocks » LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

Stock Price: $2.27 USD -0.14 (-5.81%)
Updated May 12, 2021 4:00 PM EDT - Market closed
Market Cap 407.35M
Revenue (ttm) 1.83M
Net Income (ttm) -20.65M
Shares Out 150.04M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $2.27
Previous Close $2.41
Change ($) -0.14
Change (%) -5.81%
Day's Open 2.36
Day's Range 2.22 - 2.42
Day's Volume 1,002,679
52-Week Range 0.73 - 3.13

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...

1 week ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

1 week ago - Business Wire

Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-related macular degeneration (AMD) with geogr...

1 week ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet...

1 week ago - Business Wire

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for ...

2 weeks ago - Business Wire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: APTX, BLRX, CYCN, PTN
2 weeks ago - PennyStocks

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...

2 weeks ago - Business Wire

The company announced a license agreement.

3 weeks ago - The Motley Fool

Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into a worldwide license and development collaboration agreement with a privately-held Immunomic Therapeutics Inc (ITI) to manufacture and develop ...

3 weeks ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CancerVaccines--VAC/Immunomic Strategic Alliance

3 weeks ago - Business Wire

ROCKVILLE, Md. & CARLSBAD, Calif.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platfo...

3 weeks ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet...

1 month ago - Business Wire

Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's (NYSE: LCTX) OpRegen has been used to treat a patient suffering from adult-onset vitel...

1 month ago - Benzinga

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCell--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for ser...

1 month ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious med...

1 month ago - Business Wire

Lineage Cell (LCTX) delivered earnings and revenue surprises of 120.00% and -73.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

2 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

2 months ago - Business Wire

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

2 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

2 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet m...

2 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #CIRM--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet m...

3 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address u...

3 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

3 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

4 months ago - Business Wire

Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious...

5 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet me...

5 months ago - Business Wire

Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and cancer-relate...

5 months ago - Seeking Alpha

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #DryAMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for seri...

5 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...

5 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious...

6 months ago - Business Wire

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...

6 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...

6 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...

6 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical...

6 months ago - Business Wire

CARLSBAD, Calif. & LONDON--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unme...

6 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

7 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

8 months ago - Business Wire

ALAMEDA, Calif. & CARLSBAD, Calif.

Other stocks mentioned: AGE
8 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

8 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

8 months ago - Business Wire

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

8 months ago - Business Wire

Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.

9 months ago - Business Wire

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute sp... [Read more...]

Industry
Biotechnology
Founded
1990
CEO
Brian Culley
Employees
49
Stock Exchange
NYSEAMERICAN
Ticker Symbol
LCTX
Full Company Profile

Financial Performance

In 2020, LCTX's revenue was $1.83 million, a decrease of -48.05% compared to the previous year's $3.52 million. Losses were -$20.65 million, 76.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 134.80% from the latest price.

Price Target
$5.33
(134.80% upside)
Analyst Consensus: Buy